Bibliography
- Kola I , LandisJ. Can the pharmaceutical industry reduce attrition rates?Nat. Rev. Drug Discov.3(8), 711–715 (2004).
- David E , TramontinT, ZemmelR. Pharmaceutical R&D: the road to positive returns.Nat. Rev. Drug Discov.8(8), 609–610 (2009).
- Lazarou J , PomeranzBH, CoreyPN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.JAMA279(15), 1200–1205 (1998).
- Gurwitz JH , FieldTS, AvornJet al. Incidence and preventability of adverse drug events in nursing homes. Am. J. Med. 109(2), 87–94 (2000).
- Ulrich RG . Idiosyncratic toxicity: a convergence of risk factors.Ann. Rev. Med.58, 17–34 (2007).
- Uetrecht J . Idiosyncratic drug reactions: past, present, and future.Chem. Res. Toxicol.21(1), 84–92 (2008).
- Uetrecht J . Evaluation of which reactive metabolite, if any, is responsible for a specific idiosyncratic reaction.Drug Metabo. Rev.38(4), 745–753 (2006).
- Ashby J , TennantRW. Prediction of rodent carcinogenicity for 44 chemicals: results.Mutagenesis9(1), 7–15 (1994).
- Baillie TA . Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology.Chem. Res. Toxicol.19(7), 889–893 (2006).
- Khetani SR , BhatiaSN. Microscale culture of human liver cells for drug development.Nat. Biotech.26(1), 120–126 (2008).
- Kamiya N , IwaoE, HiragaNet al. Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3–4A protease inhibitor. J. Gen. Virol. 91(7), 1668–1677 (2010).
- Li AP , BodeC, SakaiY. A novel in vitro system, the integrated discrete multiple organ cell culture (IdMOC) system, for the evaluation of human drug toxicity: comparative cytotoxicity of tamoxifen towards normal human cells from five major organs and MCF-7 adenocarcinoma breast cancer cells. Chem. Biol. Interac.150(1), 129–136 (2004).
- Doherty MK , HammondDE, ClagueMJ, GaskellSJ, BeynonRJ. Turnover of the human proteome: determination of protein intracellular stability by dynamic SILAC.J. Proteome Res.8(1), 104–112 (2009).
- Bantscheff M , BoescheM, EberhardD, MatthiesonT, SweetmanG, KusterB. Robust and sensitive iTRAQ quantification on an LTQ Orbitrap mass spectrometer.Mol. Cell Proteomics, 7(9), 1702–1713 (2008).
- Calleri E , TemporiniC, CaccialanzaG, MassoliniG. Target-based drug discovery: the emerging success of frontal affinity chromatography coupled to mass spectrometry.ChemMedChem4(6), 905–916 (2009).
- Salisbury CM , CravattBF. Activity-based probes for proteomic profiling of histone deacetylase complexes.Proc. Natl Acad. Sci. USA, 104(4), 1171–1176 (2007).
- Koster H , LittleDP, LuanPet al. Capture compound mass spectrometry: a technology for the investigation of small molecule protein interactions. Assay Drug Dev. Technol. 5(3), 381–390 (2007).
- Fischer JJ , MichaelisS, SchreyAKet al. Capture compound mass spectrometry sheds light on the molecular mechanisms of liver toxicity of two parkinson drugs. Toxicol. Sci. 113(1), 243–253 (2010).
- Boelsterli UA , LimPL. Mitochondrial abnormalities – a link to idiosyncratic drug hepatotoxicity?Toxicol. Appl. Pharmacol.220(1), 92–107 (2007).
- Dykens JA , MarroquinLD, WillY. Strategies to reduce late-stage drug attrition due to mitochondrial toxicity.Expert Rev. Mol. Diagn.7(2), 161–175 (2007).
- Dalhoff C , HubenM, LenzTet al. Synthesis of S-adenosyl-L-homocysteine capture compounds for selective photoinduced isolation of methyltransferases. ChemBioChem 11(2), 256–265 (2010).